Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12.
Lewis ND, Sia CL, Kirwin K, Haupt S, Mahimkar G, Zi T, Xu K, Dooley K, Jang SC, Choi B, Boutin A, Grube A, McCoy C, Sanchez-Salazar J, Doherty M, Gaidukov L, Estes S, Economides KD, Williams DE, Sathyanarayanan S.
Lewis ND, et al. Among authors: grube a.
Mol Cancer Ther. 2021 Mar;20(3):523-534. doi: 10.1158/1535-7163.MCT-20-0484. Epub 2020 Dec 21.
Mol Cancer Ther. 2021.
PMID: 33443094